This Article  • References  • Full text PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Citing articles on HighWire  • Citing articles on Web of Science (440)  • Contact me when this article is cited  Related Content  • Similar articles in JAMA  Social Bookmarking   What's this?

Results From the Postmenopausal Estrogen/Progestin Interventions (PEPI) Trial

The Writing Group for the PEPI Trial

JAMA. 1996;276(17):1389-1396.

Abstract
Objective.
—To assess the effects of hormone therapy on bone mineral density (BMD) in the spine and hip of postmenopausal women.

Design.
—A 3-year, multicenter, randomized, double-blinded, placebo-controlled clinical trial.

Participants.
—A total of 875 healthy women aged 45 to 64 years recruited at 7 clinical centers.

Interventions.
—Treatments were (1) placebo; (2) conjugated equine estrogens (CEE), 0.625 mg/d; (3) CEE, 0.625 mg/d plus medroxyprogesterone acetate (MPA), 10 mg/d for 12 d/mo; (4) CEE, 0.625 mg/d plus MPA, 2.5 mg/d daily; or (5) CEE, 0.625 mg/d plus micronized progesterone (MP), 200 mg/d for 12 d/mo.

Main Outcome Measures.
—Bone mineral density at baseline, 12 months, and 36 months.

Results.
—participants assigned to the placebo group lost an average of 1.8% of spine BMD and 1.7% of hip BMD by the 36-month visit, while those assigned to active regimens gained BMD at both sites, ranging from 3.5% to 5.0% mean total increases in spinal BMD and a mean total increase of 1.7% of BMD in the hip. Changes in BMD for women assigned to active regimens were significantly greater than those assigned to placebo. Women assigned to CEE plus continuous MPA had significantly greater increases in spinal BMD (increase of 5%) than those assigned to the other 3 active regimens (average increase, 3.8%). Findings were similar among those adhering to assigned therapy, although, among adherent participants, there were no significant differences in BMD changes among the 4 active treatment groups. Older women, women with low initial BMD, and those with no previous hormone use gained significantly more bone than younger women, women with higher initial BMD, and those who had used hormones previously.

Conclusions.
—Postmenopausal women assigned to placebo demonstrated decreased BMD at the spine and hip, whereas women assigned to estrogen therapy increased BMD during a 36-month period. These findings demonstrate that estrogen replacement therapy increases BMD at clinically important sites.

Footnotes
A list of the members of the Writing Group for the PEPI Trial appears at the end of this article.

Dr Bush serves as a consultant for Parke-Davis. Morris Plains, NJ, and has been a consultant for Eli Lilly and Co, Indianapolis, Ind; Ortho Pharmaceutical Corp, Raritan, NJ; Forest Laboratories Inc, St Louis, Mo; and Organon Inc, West Orange, NJ. Dr Bush also receives research support from Wyeth-Ayerst Laboratories,

Philadelphia, Pa, and has received research support from Rhône-Poulenc Rorer Pharmaceuticals Inc, Collegeville, Pa; and The Upjohn Co, Kalamazoo, Mich.

Reprints: Irma Mebane-Sims, PhD, National Heart, Lung, and Blood Institute, National Institutes of Health, 2 Rockledge Centre, Suite 10193, 6701 Rockledge Dr, MSC 7956, Bethesda, MD 20892-7956 (e-mail: im2a@nih.gov).

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Reassessing Benefits and Risks of Hormone Therapy
Gass et al.
AMERICAN JOURNAL OF LIFESTYLE MEDICINE 2009;3:29-43.
ABSTRACT  

Osteoporosis: Management and Treatment Strategies for Orthopaedic Surgeons
Gehrig et al.
JBJS 2008;90:1362-1374.
FULL TEXT  

Bone Growth and Turnover in Progesterone Receptor Knockout Mice
Rickard et al.
Endocrinology 2008;149:2383-2390.
ABSTRACT | FULL TEXT  

Depression, the Metabolic Syndrome and Cardiovascular Risk
Vaccarino et al.
Psychosom. Med. 2008;70:40-48.
ABSTRACT | FULL TEXT  

Novel Perspectives for Progesterone in Hormone Replacement Therapy, with Special Reference to the Nervous System
Schumacher et al.
Endocr. Rev. 2007;28:387-439.
ABSTRACT | FULL TEXT  

Historical Perspectives in Postmenopausal Hormone Therapy: Defining the Right Dose and Duration
Warren
Mayo Clin Proc. 2007;82:219-226.
ABSTRACT | FULL TEXT  

Ten-year GH replacement increases bone mineral density in hypopituitary patients with adult onset GH deficiency
Gotherstrom et al.
Eur J Endocrinol 2007;156:55-64.
ABSTRACT | FULL TEXT  

Combined Oral Contraceptives in Women with Systemic Lupus Erythematosus
Petri et al.
NEJM 2005;353:2550-2558.
ABSTRACT | FULL TEXT  

The prevention of osteoporotic fractures
Karlsson et al.
J Bone Joint Surg Br 2005;87-B:1320-1327.
FULL TEXT  

Osteopenia: To Treat or Not To Treat?
McClung
ANN INTERN MED 2005;142:796-7.
FULL TEXT  

Bone Density-related Predictors of Blood Lead Level among Peri- and Postmenopausal Women in the United States: The Third National Health and Nutrition Examination Survey, 1988-1994
Nash et al.
Am J Epidemiol 2004;160:901-911.
ABSTRACT | FULL TEXT  

Relationship of Physical Fitness vs Body Mass Index With Coronary Artery Disease and Cardiovascular Events in Women
Wessel et al.
JAMA 2004;292:1179-1187.
ABSTRACT | FULL TEXT  

Hormone Replacement Therapy
Lochner and Einhorn
J Am Acad Orthop Surg 2004;12:291-294.
FULL TEXT  

National Trends in Osteoporosis Visits and Osteoporosis Treatment, 1988-2003
Stafford et al.
Arch Intern Med 2004;164:1525-1530.
ABSTRACT | FULL TEXT  

Fracture Incidence in Relation to the Pattern of Use of Hormone Therapy in Postmenopausal Women
Banks et al.
JAMA 2004;291:2212-2220.
ABSTRACT | FULL TEXT  

A Comparison of the Effects of Raloxifene and Conjugated Equine Estrogen on Bone and Lipids in Healthy Postmenopausal Women
Reid et al.
Arch Intern Med 2004;164:871-879.
ABSTRACT | FULL TEXT  

The WHI Estrogen-Alone Trial--Do Things Look Any Better?
Hulley and Grady
JAMA 2004;291:1769-1771.
FULL TEXT  

The Impact of Monitoring on Adherence and Persistence with Antiresorptive Treatment for Postmenopausal Osteoporosis: A Randomized Controlled Trial
Clowes et al.
J. Clin. Endocrinol. Metab. 2004;89:1117-1123.
ABSTRACT | FULL TEXT  

Estradiol and Selective Estrogen Receptor Modulators Differentially Regulate Target Genes with Estrogen Receptors {alpha} and {beta}
Kian Tee et al.
Mol. Biol. Cell 2004;15:1262-1272.
ABSTRACT | FULL TEXT  

Effects of Alendronate and Hormone Replacement Therapy, Alone and in Combination, on Bone Mass and Markers of Bone Turnover in Elderly Women with Osteoporosis
Evio et al.
J. Clin. Endocrinol. Metab. 2004;89:626-631.
ABSTRACT | FULL TEXT  

Osteoporosis: An Under-appreciated Complication of Diabetes
Brown and Sharpless
Clin. Diabetes 2004;22:10-20.
ABSTRACT | FULL TEXT  

Soy Phytoestrogens Do Not Prevent Bone Loss in Postmenopausal Monkeys
Register et al.
J. Clin. Endocrinol. Metab. 2003;88:4362-4370.
ABSTRACT | FULL TEXT  

Effects of specific post-menopausal hormone therapies on bone mineral density in post-menopausal women: a meta-analysis
Doren et al.
Hum Reprod 2003;18:1737-1746.
ABSTRACT | FULL TEXT  

Osteoporosis: A Pharmacotherapy Update
Brown
Journal of Pharmacy Practice 2003;16:164-169.
ABSTRACT  

Combination Therapy With Hormone Replacement and Alendronate for Prevention of Bone Loss in Elderly Women: A Randomized Controlled Trial
Greenspan et al.
JAMA 2003;289:2525-2533.
ABSTRACT | FULL TEXT  

Lignes directrices de pratique clinique 2002 pour le diagnostic et le traitement de l'osteoporose au Canada
Brown and Josse
CMAJ 2003;168:SF1-38.
ABSTRACT | FULL TEXT  

Understanding the Divergent Data on Postmenopausal Hormone Therapy
Grodstein et al.
NEJM 2003;348:645-650.
FULL TEXT  

Short-Term, High-Dose Parathyroid Hormone-Related Protein as a Skeletal Anabolic Agent for the Treatment of Postmenopausal Osteoporosis
Horwitz et al.
J. Clin. Endocrinol. Metab. 2003;88:569-575.
ABSTRACT | FULL TEXT  

Significant Differential Effects of Alendronate, Estrogen, or Combination Therapy on the Rate of Bone Loss after Discontinuation of Treatment of Postmenopausal Osteoporosis: A Randomized, Double-Blind, Placebo-Controlled Trial
Greenspan et al.
ANN INTERN MED 2002;137:875-883.
ABSTRACT | FULL TEXT  

2002 clinical practice guidelines for the diagnosis and management of osteoporosis in Canada
Brown and Josse
CMAJ 2002;167:s1-34.
ABSTRACT | FULL TEXT  

Effect of Discontinuation of Estrogen, Calcitriol, and the Combination of Both on Bone Density and Bone Markers
Gallagher et al.
J. Clin. Endocrinol. Metab. 2002;87:4914-4923.
ABSTRACT | FULL TEXT  

Clinical Use of Bone Densitometry: Scientific Review
Cummings et al.
JAMA 2002;288:1889-1897.
ABSTRACT | FULL TEXT  

The Biology, Medical Management, and Podiatric Implications of Menopause
Friedlander and Jones
J. Am. Podiatr. Med. Assoc. 2002;92:437-443.
ABSTRACT | FULL TEXT  

V. Meta-Analysis of the Efficacy of Hormone Replacement Therapy in Treating and Preventing Osteoporosis in Postmenopausal Women
Wells et al.
Endocr. Rev. 2002;23:529-539.
FULL TEXT  

Noncardiovascular Disease Outcomes During 6.8 Years of Hormone Therapy: Heart and Estrogen/Progestin Replacement Study Follow-up (HERS II)
Hulley et al.
JAMA 2002;288:58-64.
ABSTRACT | FULL TEXT  

Osteoporosis and Diabetes
Chau and Edelman
Clin. Diabetes 2002;20:153-157.
FULL TEXT  

Alveolar and Postcranial Bone Density in Postmenopausal Women Receiving Hormone/Estrogen Replacement Therapy: A Randomized, Double-blind, Placebo-Controlled Trial
Civitelli et al.
Arch Intern Med 2002;162:1409-1415.
ABSTRACT | FULL TEXT  

Genetics of Osteoporosis
Peacock et al.
Endocr. Rev. 2002;23:303-326.
ABSTRACT | FULL TEXT  

Effect of Lower Doses of Conjugated Equine Estrogens With and Without Medroxyprogesterone Acetate on Bone in Early Postmenopausal Women
Lindsay et al.
JAMA 2002;287:2668-2676.
ABSTRACT | FULL TEXT  

A 60-Year-Old Woman Trying to Discontinue Hormone Replacement Therapy
Grady
JAMA 2002;287:2130-2137.
FULL TEXT  

Barriers to Osteoporosis Identification and Treatment Among Primary Care Physicians and Orthopedic Surgeons
Simonelli et al.
Mayo Clin Proc. 2002;77:334-338.
ABSTRACT  

Bone Mass Response to Discontinuation of Long-term Hormone Replacement Therapy: Results From the Postmenopausal Estrogen/Progestin Interventions (PEPI) Safety Follow-up Study
Greendale et al.
Arch Intern Med 2002;162:665-672.
ABSTRACT | FULL TEXT  

Recognition of Osteoporosis by Primary Care Physicians
Gehlbach et al.
AJPH 2002;92:271-273.
ABSTRACT | FULL TEXT  

Guidelines on the management of osteoporosis associated with chronic liver disease
Collier et al.
Gut 2002;50:i1-9.
FULL TEXT  

The physiology, medical management and oral implications of menopause
FRIEDLANDER
Journal of the American Dental Association 2002;133:73-81.
ABSTRACT | FULL TEXT  

Growth Hormone and Sex Steroid Effects on Bone Metabolism and Bone Mineral Density in Healthy Aged Women and Men
Christmas et al.
Journals of Gerontology Series A: Biological Sciences and Medical Sciences 2002;57:M12-18.
ABSTRACT | FULL TEXT  

Hormone Replacement Therapy and Dry Eye Syndrome
Schaumberg et al.
JAMA 2001;286:2114-2119.
ABSTRACT | FULL TEXT  

Selective Estrogen Receptor Modulation and Reduction in Risk of Breast Cancer, Osteoporosis, and Coronary Heart Disease
Jordan et al.
JNCI J Natl Cancer Inst 2001;93:1449-1457.
ABSTRACT | FULL TEXT  

High Resolution Screening of Plant Natural Product Extracts for Estrogen Receptor a and f3 Binding Activity Using an Online HPLC-MS Biochemical Detection System
Schobel et al.
J Biomol Screen 2001;6:291-303.
ABSTRACT  

Prevention of Bone Loss with Tibolone in Postmenopausal Women: Results of Two Randomized, Double-Blind, Placebo-Controlled, Dose-Finding Studies
Gallagher et al.
J. Clin. Endocrinol. Metab. 2001;86:4717-4726.
ABSTRACT | FULL TEXT  

Bone Mineral Density Response to Estrogen Replacement in Frail Elderly Women: A Randomized Controlled Trial
Villareal et al.
JAMA 2001;286:815-820.
ABSTRACT | FULL TEXT  

Combination Treatment with Estrogen and Calcitriol in the Prevention of Age-Related Bone Loss
Gallagher et al.
J. Clin. Endocrinol. Metab. 2001;86:3618-3628.
ABSTRACT | FULL TEXT  

Hormone Replacement Therapy and Prevention of Nonvertebral Fractures: A Meta-analysis of Randomized Trials
Torgerson and Bell-Syer
JAMA 2001;285:2891-2897.
ABSTRACT | FULL TEXT  

Postmenopausal Hormone Therapy for Prevention of Fractures: How Good Is the Evidence?
Grady and Cummings
JAMA 2001;285:2909-2910.
FULL TEXT  

Hormone replacement therapy (HRT)-- risks and benefits
Barrett-Connor and Stuenkel
Int J Epidemiol 2001;30:423-426.
FULL TEXT  

Fracture History and Risk of Breast and Endometrial Cancer
Newcomb et al.
Am J Epidemiol 2001;153:1071-1078.
ABSTRACT | FULL TEXT  

Effect of Combined Risedronate and Hormone Replacement Therapies on Bone Mineral Density in Postmenopausal Women
Harris et al.
J. Clin. Endocrinol. Metab. 2001;86:1890-1897.
ABSTRACT | FULL TEXT  

Factors Associated with Age at Natural Menopause in a Multiethnic Sample of Midlife Women
Gold et al.
Am J Epidemiol 2001;153:865-874.
ABSTRACT | FULL TEXT  

Treatment of Postmenopausal Osteoporosis
Altkorn and Vokes
JAMA 2001;285:1415-1418.
FULL TEXT  

Effects of Contraceptive Use on Bone Biochemical Markers in Young Women
Ott et al.
J. Clin. Endocrinol. Metab. 2001;86:179-185.
ABSTRACT | FULL TEXT  

Sex Steroids and Bone
Compston
Physiol. Rev. 2001;81:419-447.
ABSTRACT | FULL TEXT  

How Many Women Lose Bone Mineral Density While Taking Hormone Replacement Therapy?: Results From the Postmenopausal Estrogen/Progestin Interventions Trial
Greendale et al.
Arch Intern Med 2000;160:3065-3071.
ABSTRACT | FULL TEXT  

Weight cycling and high-density lipoprotein cholesterol in women: evidence of an adverse effect: A report from the NHLBI-sponsored WISE study
Olson et al.
J Am Coll Cardiol 2000;36:1565-1571.
ABSTRACT | FULL TEXT  

Provocative relation between soy and bone maintenance
Erdman et al.
Am. J. Clin. Nutr. 2000;72:679-680.
FULL TEXT  

The Role of Hormone Replacement Therapy in the Prevention of Postmenopausal Heart Disease
Mosca
Arch Intern Med 2000;160:2263-2272.
ABSTRACT | FULL TEXT  

Editorial: Sequential Parathyroid Hormone/Alendronate Therapy for Osteoporosis--Robbing Peter to Pay Paul?
Horwitz et al.
J. Clin. Endocrinol. Metab. 2000;85:2127-2128.
FULL TEXT  

Comparison of Pharmacokinetics of a Conjugated Equine Estrogen Preparation (Premarin) and a Synthetic Mixture of Estrogens (C.E.S.) in Postmenopausal Women
Bhavnani et al.
Reproductive Sciences 2000;7:175-183.
ABSTRACT  

Hormone replacement therapy: discrepancies between evidence and recommendations
Hemminki
Scand J Public Health 2000;28:81-83.
ABSTRACT  

Effects of continuous conjugated estrogen and micronized progesterone therapy upon lipoprotein metabolism in postmenopausal women
Wolfe et al.
J. Lipid Res. 2000;41:368-375.
ABSTRACT | FULL TEXT  

Risk of breast cancer associated with hormone replacement therapy
Dopp and Kolesar
J Oncol Pharm Pract 1999;5:109-116.
ABSTRACT  

Addition of Alendronate to Ongoing Hormone Replacement Therapy in the Treatment of Osteoporosis: A Randomized, Controlled Clinical Trial
Lindsay et al.
J. Clin. Endocrinol. Metab. 1999;84:3076-3081.
ABSTRACT | FULL TEXT  

Therapy for Fracture Prevention
McClung
JAMA 1999;282:687-689.
FULL TEXT  

Individualizing Therapy to Prevent Long-term Consequences of Estrogen Deficiency in Postmenopausal Women
Col et al.
Arch Intern Med 1999;159:1458-1466.
ABSTRACT | FULL TEXT  

Hormone Replacement Therapy and Risk of Breast Cancer With a Favorable Histology: Results of the Iowa Women's Health Study
Gapstur et al.
JAMA 1999;281:2091-2097.
ABSTRACT | FULL TEXT  

Alternatives to the Use of Estrogen in Postmenopausal Women
Pinkerton and Santen
Endocr. Rev. 1999;20:308-320.
ABSTRACT | FULL TEXT  

Postmenopausal Hormone Replacement Therapy: Effect on Diagnosis and Outcome in Early-Stage Invasive Breast Cancer Treated With Conservative Surgery and Radiation
Fowble et al.
JCO 1999;17:1680-1680.
ABSTRACT | FULL TEXT  

Effect of Testosterone Treatment on Bone Mineral Density in Men Over 65 Years of Age
Snyder et al.
J. Clin. Endocrinol. Metab. 1999;84:1966-1972.
ABSTRACT | FULL TEXT  

A Mouse Model to Study the Effects of Hormone Replacement Therapy on Normal Mammary Gland during Menopause: Enhanced Proliferative Response to Estrogen in Late Postmenopausal Mice
Raafat et al.
Endocrinology 1999;140:2570-2580.
ABSTRACT | FULL TEXT  

A 73-Year-Old Woman With Osteoporosis
Greenspan
JAMA 1999;281:1531-1540.
FULL TEXT  

Prevention of Femoral and Lumbar Bone Loss with Hormone Replacement Therapy and Vitamin D3 in Early Postmenopausal Women: A Population-Based 5-Year Randomized Trial
Komulainen et al.
J. Clin. Endocrinol. Metab. 1999;84:546-552.
ABSTRACT | FULL TEXT  

Generation and reproductive phenotypes of mice lacking estrogen receptor beta
Krege et al.
Proc. Natl. Acad. Sci. USA 1998;95:15677-15682.
ABSTRACT | FULL TEXT  

Fortnightly review: Hormone replacement therapy
Barrett-Connor
BMJ 1998;317:457-461.
FULL TEXT  

Hormone replacement therapy and risk of hip fracture: population based case-control study
Michaëlsson et al.
BMJ 1998;316:1858-1863.
ABSTRACT | FULL TEXT  

Treatment of Postmenopausal Osteoporosis
Eastell
NEJM 1998;338:736-746.
FULL TEXT  

Facilitating Patient-Specific Decisions Regarding Hormone Replacement Therapy
Weiss
JAMA 1997;278:475-475.
ABSTRACT  

The Predictive Value of Biochemical Markers of Bone Turnover for Bone Mineral Density in Early Postmenopausal Women Treated with Hormone Replacement or Calcium Supplementation
Rosen et al.
J. Clin. Endocrinol. Metab. 1997;82:1904-1910.
ABSTRACT | FULL TEXT  

Estrogen Replacement Therapy: New Options, Continuing Concerns
Hanson and Melzer
JAMA 1997;277:1515-1515.
ABSTRACT  

Patient-Specific Decisions About Hormone Replacement Therapy in Postmenopausal Women
Col et al.
JAMA 1997;277:1140-1147.
ABSTRACT  

Skeletal Effects of Cyclic Recombinant Human Growth Hormone and Salmon Calcitonin in Osteopenic Postmenopausal Women
Holloway et al.
J. Clin. Endocrinol. Metab. 1997;82:1111-1117.
ABSTRACT | FULL TEXT  

Estrogen Raises Bone Density: Data from PEPI
JWatch Women's Health 1997;1997:3-3.
FULL TEXT  

Boning Up on Estrogen: New Options, New Concerns
Insogna et al.
JAMA 1996;276:1430-1432.
ABSTRACT